First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study

Yi-Long WuHye Ryun KimRoss A. SooQing ZhouHiroaki AkamatsuGee-Chen ChangChao-Hua ChiuHidetoshi HayashiSang-We KimYasushi GotoTerufumi KatoJianying ZhouVictor Ho-Fun LeeMakoto NishioBaohui HanDong-Wan KimShun LuAnna PolliJean-François MartiniFrancesca ToffalorioChew Hooi WongTony Mok2026-02-052026-02-052025-0710.1016/j.jtho.2025.02.021https://scholars.csmu.edu.tw/handle/123456789/5286[SDGs]SDG3First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Studyjournal-article